Capecitabine and Trastuzumab for Metastatic Breast Cancer
Trastuzumab (Herceptin - Genentech), a recombinant 'humanized' monoclonal antibody (rhuMAb) that binds to a protein encoded by the oncogene HER2, and capecitabine (ka pe site' a been; Xeloda - Roche), an oral pro-drug for 5-fluorouracil, have been approved by the FDA for treatment of metastatic breast cancer....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Capecitabine and Trastuzumab for Metastatic Breast Cancer
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1039
Article Code: 1039b
Date: November 6, 1998
Volume: 40
Pages: 106-108
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1039
Article Code: 1039b
Date: November 6, 1998
Volume: 40
Pages: 106-108
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)